The United Kingdom and the United States have forged a major trade agreement that will ensure no duties on UK drug shipments going into the American market.
The Terms of the Accord
In exchange for the tariff guarantee, the UK has pledged to raise expenditure on pharmaceuticals through the public health system. This pledge secures that duties on these vital exports will stay at nothing for a period of 36 months.
This agreement is in response to recent warnings to dramatically increase import taxes on patented pharmaceutical products, with potential rates discussed up to 100%.
"This deal between the United Kingdom reinforces the worldwide climate for cutting-edge drugs and introduces much-needed fairness to transatlantic drug exports," a release noted.
Commercial Importance
Pharmaceuticals are one of the Britain's biggest exports to the America, which is easily the largest market for large companies like GSK and AstraZeneca.
Trade data reveal that in the one-year period leading up to September, the UK shipped medicines totaling £11.1bn to the US. This figure accounted for a significant portion of British export trade in that period.
"This deal secures work, boosts funding and paves the way for the UK to emerge as a worldwide center for medical research," a minister commented.
Specific UK Commitments
The deal involves several notable changes from the United Kingdom:
- Price Threshold Increase: The UK will lift the cost ceiling at which it deems new medicines to be too expensive by twenty-five percent.
- Higher Drug Budget: There is a aim to double total NHS spending on drugs from 0.3 percent of GDP to 0.6 percent over the following ten-year period.
- Refund Ceiling: The sum pharmaceutical firms must refund to the NHS to stay within budget will be restricted at fifteen percent. In the past, rebates were more than 20%.
Recent Tensions
The pact follows a ongoing row between the drug companies and the UK government over drug pricing and approval rates.
This friction were heightened by claims that US consumers were paying several times more for the same drugs than consumers in the Britain and the EU.
Over the last 18 months, several major drug company projects in the UK have been paused or abandoned, while multi-billion-dollar investments have been announced toward US facilities.
A senior figure acknowledged that the NHS had to spend more on drugs, noting that its expenditure on drugs had declined as a percentage of its resources over the previous ten-year period.
